Corbus Pharmaceuticals: Blocking TGFβ with CRB-601: A New Play for an Old Target
About The Event
Join us for the first in the series of virtual opportunities to ‘Meet the Expert’ with Corbus Pharmaceuticals, featuring Jeffrey Clarke, MD (Duke University School of Medicine) and Joan Seoane, PhD (Vall d’Hebron Institute of Oncology). These specialists will discuss the challenges and potential opportunities in targeting Transforming Growth Factor β (TGFβ) in Oncology. Dr Clarke is a leading expert in the area of immuno-oncology in the setting of NSCLC, and Dr Seoane has published extensively on the role of TGFβ in tumor immunosuppression and development of translational tools to guide treatment.
This event will focus on CRB-601, an anti-integrin αvβ8 monoclonal antibody that blocks the activation of latent-TGFβ expressed within the tumor microenvironment. This blockade is designed to reduce local TGFβ levels that are known to promote tumor growth. In non-clinical studies, CRB-601 significantly inhibits tumor growth both as a single agent and in combination(s). CRB-601 is scheduled for IND and first in human in 2H/2023.
A live Q&A session will follow the formal presentations.
Stay tuned, for the next ‘Meet the Expert’ event hosted by Corbus Pharmaceuticals where we will focus on their clinical asset CRB-701. A 3rd generation ADC, targeting Nectin-4 positive cancers.